Lonza Acquires Genentech Biopharma Plant in Spain

摘要

Lonza says it has agreed to acquire Genentech's mammalian-cell biopharmaceutical manufacturing facility at Porrino,Spain for 150 million,and as part of the agreement with Genentech it will build a large-scale biopharma plant in Singapore.The investment figure for the Singapore plant was not disclosed.Announcement of the deal comes immediately after Lonza's agreement to buy Cambrex's bio-products and biopharma divisions,including more biopharma manufacturing capacity,for 460 million (CW.Nov.1,p.8).The Genentech deal would provide Lonza with biopharma capacity far beyond that of any other biopharma contract manufacturer that is not also a drug company.The plant at Porrino is one of three Genentech plants currently used to produce the company's Avastin cancer treatment.